The booklet is now available in five additional languages (Hindi, Kannada, Malayalam, Tamil and Telugu) at select clinics and via QR codes for digital access.... Mar 18
On track towards Vision 2030 Solid revenue growth of 17% on the back of Line 3 in CDMO sterile Injectables EBITDA margins to expand going ... Feb 06
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen ... Oct 15
In the first half of 2025, Fosun’s four core subsidiaries generated a total revenue of RMB63.61 billion, with their contribution to the Group’... Sep 01
While the actual reduction in drug prices will depend on how manufacturers and distributors implement the GST cut, the potential savings could bring much-needed ... Sep 17
With better survival rates, fewer adverse effects, and enhanced precision, IMRT represents a significant step forward in lung cancer treatment.... Jul 02
As the ZM008-001 clinical trial progresses, the medical community eagerly awaits the results, which could lead the way for a new era in cancer ... Jun 13
Despite having never smoked, she developed lung cancer that spread to her eyes, illustrating the unpredictable and invasive nature of the disease.... Jun 12
Latest Pharma News Update... Aug 31
This approval follows a priority review designation by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) and marks the first ... Jun 23
Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options... May 08
Poziotonib was also presented at European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021 ... Mar 15
In 2018, the FDA approved LORBRENA for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least ... Mar 05
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people ... Jan 15
New option extends dosing from two to four weeks, reducing medical visits and improving patient convenience ... Jan 15
LORBRENA is a third-generation ALK inhibitor specifically developed to inhibit the most common tumour mutations that drive resistance to current medications and to address ... Dec 29
Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%... Dec 21
Amgen today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sotorasib, an investigational KRASG12C ... Dec 17
This new dosing option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and once approved, will be available to ... Dec 15
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations... Dec 03
... Nov 19
European Commission decision marks the first time a dual immunotherapy with limited chemotherapy is approved for patients with non-small cell lung cancer in the ... Nov 09
This acquisition is well positioned to achieve its maximum potential to benefit appropriate cancer patients in need... Nov 06
Libtayo is indicated for advanced non-smal cell cancer with PD-L1 Expression of ≥50%... Oct 31
Roche receives FDA approval for the cobas EGFR mutation test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with ... Oct 30
-Advertisements-
.jpeg)
Tuesday, October 06, 2026
_11zon.png)
.png)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
